| 000 | 01596 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517210304.0 | ||
| 264 | 0 | _c20190403 | |
| 008 | 201904s 0 0 eng d | ||
| 022 | _a2047-2927 | ||
| 024 | 7 |
_a10.1111/andr.12485 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDefreyne, J | |
| 245 | 0 | 0 |
_aProspective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence. _h[electronic resource] |
| 260 |
_bAndrology _c05 2018 |
||
| 300 |
_a446-454 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCyproterone Acetate _xtherapeutic use |
| 650 | 0 | 4 |
_aEstradiol _xtherapeutic use |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHematocrit |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aReference Values |
| 650 | 0 | 4 | _aGender-Affirming Procedures |
| 650 | 0 | 4 |
_aTestosterone _xtherapeutic use |
| 650 | 0 | 4 | _aTransgender Persons |
| 700 | 1 | _aVantomme, B | |
| 700 | 1 | _aVan Caenegem, E | |
| 700 | 1 | _aWierckx, K | |
| 700 | 1 | _aDe Blok, C J M | |
| 700 | 1 | _aKlaver, M | |
| 700 | 1 | _aNota, N M | |
| 700 | 1 | _aVan Dijk, D | |
| 700 | 1 | _aWiepjes, C M | |
| 700 | 1 | _aDen Heijer, M | |
| 700 | 1 | _aT'Sjoen, G | |
| 773 | 0 |
_tAndrology _gvol. 6 _gno. 3 _gp. 446-454 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/andr.12485 _zAvailable from publisher's website |
| 999 |
_c28235347 _d28235347 |
||